
Tirzepatide 2.5 mg Once-Weekly Injection | Type 2 Diabetes Management | Phoenix Exim β Pharmaceutical Exporter from Nagpur, India
Mounjaro 2.5 mg Prefilled Pen contains tirzepatide, a prescription injectable medicine administered subcutaneously once weekly. In the U.S. labeling, Mounjaro is indicated as an adjunct to diet and exercise to improve blood-glucose control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Phoenix Exim, based in Nagpur, India, supplies pharmaceutical and healthcare products for international B2B requirements, including markets such as USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable import, registration, prescription, labeling and regulatory requirements.
1. π GENERAL INFORMATION
Mounjaro 2.5 mg is a prescription medicine containing Tirzepatide, a dual GIP and GLP-1 receptor agonist.
The 2.5 mg strength is used as the recommended starting dose in the U.S. prescribing information. It is administered once weekly and is designed for treatment initiation rather than ongoing glycemic control. After 4 weeks, the recommended dose is generally increased to 5 mg once weekly under medical supervision.
β¦ Product Highlights
Prescription injectable medicine
Active ingredient: Tirzepatide
Starting strength: 2.5 mg
Prefilled single-dose pen presentation
Subcutaneous administration
Once-weekly dosing
Used as part of a comprehensive type 2 diabetes treatment plan
Manufactured by Eli Lilly and Company for applicable markets
2. π PRODUCT INFORMATION
| Product Detail | Information |
|---|---|
| Brand | Mounjaro |
| Active Ingredient | Tirzepatide |
| Strength | 2.5 mg |
| Dosage Form | Injection |
| Device | Prefilled Single-Dose Pen |
| Route | Subcutaneous |
| Dosing Frequency | Once weekly |
| Therapeutic Class | GIP/GLP-1 Receptor Agonist |
| Primary U.S. Indication | Type 2 Diabetes Mellitus |
| Origin | Market-dependent |
| Exporter | Phoenix Exim |
| Supply Base | Nagpur, Maharashtra, India |
The U.S. FDA labeling specifies 2.5 mg/0.5 mL for the single-dose pen presentation. Product presentations and regulatory status can differ between countries, so buyers should verify the exact pack and market authorization.
3. π― USES OF MOUNJARO 2.5 MG
πΉ Type 2 Diabetes Management
Mounjaro is used together with diet and exercise to improve glycemic control in people with type 2 diabetes mellitus.
πΉ Treatment Initiation
The 2.5 mg dose is primarily a starting dose intended to help patients begin treatment and adjust to tirzepatide. It is not intended as the maintenance dose for glycemic control in the U.S. labeling.
πΉ Comprehensive Diabetes Care
Mounjaro may be incorporated into an overall diabetes-management plan that includes appropriate nutrition, physical activity, monitoring and other treatments when prescribed.
Important: The approved indications and labeling for tirzepatide vary by country. Use should follow the product's approved local labeling.
4. β BENEFITS OF MOUNJARO 2.5 MG
When prescribed appropriately, tirzepatide offers several clinically relevant benefits.
β Supports Blood-Glucose Management
Mounjaro helps improve glycemic control when used with diet and exercise in people with type 2 diabetes.
β Dual GIP + GLP-1 Activity
Tirzepatide activates both GIP and GLP-1 receptors, providing its characteristic metabolic effects.
β Convenient Once-Weekly Administration
The medicine is administered once weekly rather than requiring daily injections.
β Prefilled Pen Convenience
The single-dose prefilled pen provides a convenient delivery format for prescribed subcutaneous administration.
β Structured Dose Escalation
Starting at 2.5 mg allows treatment to be initiated at a lower dose before moving to higher doses according to the prescribing schedule and medical supervision.
5. β οΈ SIDE EFFECTS OF MOUNJARO
Mounjaro can cause adverse reactions, particularly gastrointestinal effects.
Possible side effects include:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion/dyspepsia
Abdominal pain
These are among the most common adverse reactions identified in the U.S. prescribing information.
Serious adverse reactions can also occur. Patients should review the complete prescribing information and discuss individual risks with their healthcare professional.
6. πΈ COMMON SIDE EFFECTS
The most common side effects include:
Nausea β’ Diarrhea β’ Decreased Appetite β’ Vomiting β’ Constipation β’ Dyspepsia β’ Abdominal Pain
Gastrointestinal symptoms can be particularly noticeable during dose initiation or escalation. Medical advice should be sought if symptoms are severe, persistent, or concerning.
7. π HOW TO USE MOUNJARO 2.5 MG
Mounjaro should be used exactly according to the prescribing information and instructions provided by a healthcare professional.
General Administration Information
1. Once Weekly
Mounjaro is administered once per week, at any time of day, with or without meals.
2. Subcutaneous Injection
It is injected under the skin rather than into a vein or muscle.
3. Injection Areas
The abdomen or thigh can be used for self-injection. Another person may administer it into the back of the upper arm. Injection sites should be rotated.
4. Starting Dose
The recommended starting dose is 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly according to the U.S. prescribing information.
5. Missed Dose
According to the manufacturer's patient information, a missed dose can generally be taken within 4 days (96 hours); if more than 4 days have passed, it should be skipped and the next scheduled dose taken. Two doses should not be taken within 3 days of each other.
8. βοΈ HOW DOES MOUNJARO WORK?
Mounjaro contains tirzepatide, which acts as an agonist at both the:
𧬠GIP Receptor
Tirzepatide activates glucose-dependent insulinotropic polypeptide receptors.
𧬠GLP-1 Receptor
It also activates glucagon-like peptide-1 receptors.
π¬ Combined Metabolic Action
This dual-receptor activity contributes to the medicine's effects on glucose regulation, appetite and gastrointestinal processes.
Tirzepatide also delays gastric emptying, which can affect the absorption of some oral medicines.
9. π‘οΈ IMPORTANT SAFETY ADVICE
π¨ Thyroid C-Cell Tumor Warning
Mounjaro carries a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. It is unknown whether this applies to humans.
Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
β οΈ Gastrointestinal Effects
Mounjaro can cause gastrointestinal adverse reactions. It is not recommended in patients with severe gastroparesis according to the U.S. prescribing information.
π©Ί Pancreatitis
Patients should be evaluated promptly if symptoms suggestive of pancreatitis occur, such as persistent severe abdominal pain.
π‘ Gallbladder Problems
Gallbladder-related events, including cholelithiasis, have occurred during clinical trials.
ποΈ Diabetic Retinopathy
Patients with a history of diabetic retinopathy should be appropriately monitored for progression.
π Oral Medicines
Because tirzepatide delays gastric emptying, it may affect the absorption of some oral medicines.
π€° Pregnancy
Mounjaro may cause fetal harm based on animal studies. Patients who are pregnant or planning pregnancy should discuss treatment with their healthcare professional.
π Oral Contraceptives
The U.S. prescribing information advises individuals using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation.
ποΈ Do Not Share the Pen
A Mounjaro KwikPen should never be shared between patients, even if the needle is changed.
βοΈ Storage
For the U.S. single-dose pen, storage is generally in a refrigerator at 2Β°Cβ8Β°C (36Β°Fβ46Β°F). The pen may be kept at room temperature up to 30Β°C (86Β°F) for up to 21 days under the U.S. instructions. Do not freeze.
10. β FREQUENTLY ASKED QUESTIONS
Q1. What is Mounjaro 2.5 mg?
Mounjaro 2.5 mg is a prescription injectable medicine containing tirzepatide, a dual GIP/GLP-1 receptor agonist.
Q2. What is Mounjaro used for?
In the U.S., Mounjaro is indicated with diet and exercise to improve blood-glucose control in adults and pediatric patients aged 10 years and older with type 2 diabetes.
Q3. Is 2.5 mg the starting dose?
Yes. The U.S. prescribing information recommends 2.5 mg once weekly as the starting dose for 4 weeks, followed by 5 mg once weekly.
Q4. How often is Mounjaro injected?
Mounjaro is administered once weekly.
Q5. Can Mounjaro be taken with food?
Yes. It can be administered at any time of day, with or without meals.
Q6. What are the common side effects?
Common adverse reactions include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.
Q7. Can the Mounjaro pen be shared?
No. The pen must not be shared between patients, even if the needle is changed.
Q8. Does Mounjaro require refrigeration?
The U.S. instructions specify refrigeration at 2Β°Cβ8Β°C. The single-dose pen can be kept at room temperature up to 30Β°C for up to 21 days under those instructions.
Q9. Is Mounjaro a prescription medicine?
Yes. Mounjaro is a prescription medicine.
Q10. Can Mounjaro be exported internationally?
International pharmaceutical requirements differ by destination. Buyers should verify product registration, import authorization, prescription status, cold-chain requirements, labeling, documentation, customs procedures and local regulatory requirements before purchase.
11. π SUBSTITUTE / ALTERNATIVE PRODUCTS
There is no universal one-to-one substitute for Mounjaro. Possible alternatives depend on the patient's diagnosis, treatment goals, medical history and local availability.
Potential Therapeutic Alternatives
Other GLP-1 receptor agonists
Other GIP/GLP-1 receptor-based therapies
Other approved injectable diabetes medicines
Oral antidiabetic medicines
Insulin therapy where clinically appropriate
Products containing different active ingredients or strengths are not automatically equivalent to Mounjaro 2.5 mg.
A healthcare professional should determine whether an alternative is appropriate.
12. π SEO KEYWORDS
π Primary Product Keywords
Mounjaro 2.5 mg
Mounjaro 2.5 mg Pen
Mounjaro 2.5 mg Injection
Mounjaro Prefilled Pen
Mounjaro 2.5 mg Prefilled Pen
Tirzepatide 2.5 mg Injection
Tirzepatide 2.5 mg Pen
Tirzepatide Prefilled Pen
Mounjaro injection supplier
Tirzepatide injection supplier
π B2B Pharmaceutical Keywords
Mounjaro pharmaceutical supplier India
Mounjaro exporter India
Tirzepatide exporter India
Tirzepatide pharmaceutical supplier
Tirzepatide injection exporter
Mounjaro pen supplier India
Tirzepatide B2B supplier
Diabetes injection supplier India
Pharmaceutical injection exporter India
Injectable medicine exporter Nagpur
π International Market Keywords
Mounjaro supplier USA
Mounjaro supplier UK
Mounjaro supplier Australia
Mounjaro supplier Canada
Mounjaro supplier Singapore
Mounjaro supplier South Korea
Mounjaro supplier UAE
Tirzepatide supplier USA
Tirzepatide supplier UK
Tirzepatide supplier Australia
Tirzepatide supplier Canada
Tirzepatide supplier Singapore
Tirzepatide supplier South Korea
Tirzepatide supplier UAE
Nagpur pharmaceutical exporter
π₯ Long-Tail SEO Keywords
Mounjaro 2.5 mg prefilled pen pharmaceutical supplier India
Tirzepatide 2.5 mg injection exporter from India
Mounjaro 2.5 mg international pharmaceutical supplier
Tirzepatide prefilled pen B2B supplier India
Mounjaro 2.5 mg pharmaceutical exporter from Nagpur
Tirzepatide injection international supply
Diabetes care injection exporter from India
Tirzepatide 2.5 mg B2B pharmaceutical supplier
Mounjaro prefilled injection supplier India
Tirzepatide injectable medicine exporter India
π’ Phoenix Exim Keywords
Phoenix Exim pharmaceutical exporter
Phoenix Exim medicine exporter Nagpur
Phoenix Exim injection supplier India
Phoenix Exim Tirzepatide supplier
Phoenix Exim pharmaceutical B2B supplier
π PHOENIX EXIM β INTERNATIONAL PHARMACEUTICAL SUPPLY
Mounjaro 2.5 mg Prefilled Pen | Tirzepatide Injection
Phoenix Exim β Pharmaceutical & Healthcare Product Exporter from Nagpur, India
π International B2B Supply Markets
πΊπΈ USA
π¬π§ UK
π¦πΊ Australia
πΈπ¬ Singapore
π¨π¦ Canada
π°π· South Korea
π¦πͺ UAE
Keywords







